Syn2bioS.A.
Research and experimental development in natural sciences and engineering
Overview
Syn2bio is a company focused on research and development of innovative pharmaceuticals, specifically working on a cardiomarker project and new pharmaceutical molecules. It conducts preclinical and clinical studies, registration, and commercialization of these medical products, including a novel radiopharmaceutical for diagnosing heart diseases.
Financials
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 66.50
- High
- PLN 67.68
- Low
- PLN 64.46
- Volume
- 18.68K
- Avg. vol.
- 27.02K
- Market cap
- PLN 581.36M
- P/E ratio
- —
- EPS
- -PLN 1.08
- Shares outstanding
- 8.73M
- 52-week
- PLN 64.46 – 75.39
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLSNBIO00013
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | — | USD -3.07m | USD -2.54m |
| Q1 2026 | — | — | — |
| Q3 2025 | — | — | — |
News
Syn2bio shares enter the sWIG80 index
Syn2bio summarizes the third quarter of the fiscal year: research on the SYN2 cardiac marker in Europe on schedule, preparations to start studies in the USA
Syn2bio publishes first periodic report
Syn2bio among the best companies on the Warsaw Stock Exchange in May according to “Parkiet”
Extraordinary shareholders meeting to be held on May 19
Syn2bio already on the stock exchange floor
Industry
Bank accounts
Registered as a VAT taxpayer on 2025-10-15. Active
12 1090 1056 0000 0001 6263 8080
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 30, 2026 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
If the management board is a multi-member management board, the President of the Management Board independently, or two members of the management board acting jointly, or one member of the management board jointly with a commercial proxy, are authorized to submit declarations of will on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Anna Urszula Szymańska (63)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| GenomedS.A. | $7,373,750.46 | genomed.pl | ||
| Sidlysp. z o.o. | $4,977,649.42 | sidly.eu | ||
| Scope FluidicsS.A. | $3,082,936.61 | scopefluidics.com | ||
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| NanotheaS.A. | $115.78 | nanothea.com | ||
| MolecureS.A. | $10.77 | molecure.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-03-27 | Share capital change (100,000.00 PLN → 4,364,564.50 PLN) | |
| 2025-08-07 | Entered in the register |
FAQ
Last updated: 2026-04-04